Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer

Current Oncology

Volumn 19, Issue 5, 2012, Pages

  Hannouf, M B ^a   Brackstone, M ^a   Xie, B ^a   Zaric, G S ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adjuvant chemotherapy; Breast cancer; Clinical practice patterns

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POSTMENOPAUSE; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER;

EID: 84867079259     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1038     Document Type: Article

References (48)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society; 2011.
2. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
3. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Ver. 2.2008. Fort Washington, PA: nccn; 2008.
4. Levine M. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 2001;164:644-6.
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
6. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
7. Albain KS, Barlow WE, Ravdin PM, et al. on behalf of the Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-63.
8. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosissignature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295-302.
9. Albain KS, Barlow WE, Shak S, et al. on behalf of Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
10. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a Transatac study. J Clin Oncol 2010;28:1829-34.
11. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a Transatac study. J Clin Oncol 2010;28:1829-34.
12. Gradishar WJ, Hansen NM, Susnik B. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype dx in clinical practice. Clin Adv Hematol Oncol 2009;7:1-7.
13. Latosinsky S, Fradette K, Lix L, Hildebrand K, Turner D. Canadian breast cancer guidelines: have they made a difference? CMAJ 2007;176:771-6.
14. Fleming ID, Cooper JS, Henson D, et al., eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997: 171-80.
15. Tang LY, Nugent Z, Demers AA, Singh H. Incidence of rightsided colorectal cancer after breast cancer: a population-based study. Am J Gastroenterol 2009;104:1213-20.
16. Roos LL, Mustard CA, Nicol JP, et al. Registries and administrative data: organization and accuracy. Med Care 1993;31:201-12.
17. Roos LL Jr, Nicol JP, Cageorge SM. Using administrative data for longitudinal research: comparisons with primary data collection. J Chronic Dis 1987;40:41-9.
18. Robinson JR, Young TK, Roos LL, Gelskey DE. Estimating the burden of disease. Comparing administrative data and self-reports. Med Care 1997;35:932-47.
19. Chen Y, Semenciw R, Kliewer E, Shi Y, Mao Y. Incidence of second primary breast cancer among women with a first primary in Manitoba, Canada. Breast Cancer Res Treat 2001;67:35-40.
20. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998;158(suppl 3):S52-64.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
22. Antman K, Amato D, Wood W, et al. Selection bias in clinical trials. J Clin Oncol 1985;3:1142-7.
23. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standarddose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997;15:3171-7.
24. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994;70:352-62.
25. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 2001;54:217-24.
26. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363:263-70.
27. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Systematic review to determine whether participation in a trial influences outcome. BMJ 2005;330:1175.
28. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
29. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
30. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from nsabp B-14 and nsabp B-20. J Clin Oncol 2010;28:1677-83.
31. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007;9:R81.
32. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006;106:2337-44.
33. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
34. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;(4):CD004421.
35. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010;7:22-36.
36. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
37. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987;235:177-82.
38. Popescu NC, King CR, Kraus MH. Localization of the human ERBB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4:362-6.
39. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an ERBB-homologous gene distinct from and unlinked to the gene encoding the egf receptor. Science 1985;229:976-8.
40. Slamon DJ, Clark GM. Amplification of c-ErbB-2 and aggressive human breast tumors? Science 1988;240:1795-8.
41. Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with her2-positive, hormone-receptor-positive metastatic breast cancer-results of the electra trial. Breast 2012;21:27-33.
42. Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr Oncol 2008;15:136-42.
43. Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet 2007;369:3-5.
44. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the hera trial. Ann Oncol 2008;19:1090-6.
45. Clarke M, Collins R, Darby S, et al. on behalf of the Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
46. Cree M, Tonita J, Turner D, et al. Comparison of treatment received versus long-standing guidelines for stage iii colon and stage ii/iii rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Clin Colorectal Cancer 2009;8:141-5.
47. Baunemann Ott CL, Ratna N, Prayag R, Nugent Z, Badiani K, Navaratnam S. Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba. Curr Oncol 2011;18:e238-42.
48. Cooke AL, Appell R, Suderman K, Fradette K, Latosinsky S. Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005. Curr Oncol 2009;16:58-64.